Informations générales (source: ClinicalTrials.gov)
Analysis of Circulating Tumor Markers in Blood (ALCINA 2)
Interventional
N/A
Institut du Cancer de Montpellier - Val d'Aurelle (Voir sur ClinicalTrials)
mai 2018
mai 2023
19 octobre 2024
The circulating tumoral biomarkers in the blood are the object of numerous researches for
several decades. The potential clinical interests of these circulating biomarkers are
diagnostic, prognostic, predictive of the efficiency of targeted therapies (according to
the mutational profile of the cancer), and could allow the study of the mechanisms of
resistance under process. In the multiplicity of these blood potential biomarkers joins a
permanent evolution of the technological means used to detect them/to quantify, as well
as to estimate their clinical utility.
Etablissements
| Les établissements d'Île-de-France ayant mis à jour leurs données Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| CLCC INSTITUT CURIE | 04/09/2024 13:49:42 | Contact (sur clinicalTrials) | |||
| CLCC RENE HUGUENIN INSTITUT CURIE | 04/09/2024 13:49:28 | Contact (sur clinicalTrials) | |||
| Les établissements hors Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
| Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle - 34298 - Montpellier - France | Marc Ychou, MD, PhD | Contact (sur clinicalTrials) | |||
| ICM - 34298 - Montpellier - France | WILLIAM JACOT | Contact (sur clinicalTrials) | |||
Critères
Tous
Inclusion Criteria:
1. Patient presenting an invasive tumoral pathology (proved or suspected), whatever is
the location or the stage,
2. Man or woman ≥ 18 years,
3. Obtaining of the informed consent signed before any procedure of specific
preselection on approval.
1. Patient presenting an invasive tumoral pathology (proved or suspected), whatever is
the location or the stage,
2. Man or woman ≥ 18 years,
3. Obtaining of the informed consent signed before any procedure of specific
preselection on approval.
1. Private persons of freedom or under guardianship,
2. Patient whose regular follow-up is impossible for psychological, family, social or
geographical reasons,
3. Pregnant woman and/or breast-feeding,
4. Unaffiliated patient to Social Protection System,